These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2632134)

  • 1. Inhibiting effects of cancer sera on in vitro responses of peripheral blood lymphocytes to recombinant interleukin-2.
    Komatsu F
    Bull Tokyo Med Dent Univ; 1989 Dec; 36(4):69-74. PubMed ID: 2632134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
    Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
    J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
    Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
    Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B; Rees RC
    Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
    Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
    Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
    J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin coating of bladder tumor cells (T24) is not protective against LAK cell cytotoxicity.
    Carr ME; Sajer SA; Spaulding A
    J Lab Clin Med; 1992 Feb; 119(2):132-8. PubMed ID: 1740625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
    Nano R; Capelli E; Gerzeli G
    Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
    Han X; Itoh K; Balch CM; Pellis NR
    Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
    Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
    J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells.
    Yamauchi A; Bloom ET
    J Immunol; 1993 Nov; 151(10):5535-44. PubMed ID: 8228244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.